Cargando…

A novel workflow for cancer blood biomarker identification

BACKGROUND: Over the last few years, great progress has been made in the development of key technologies to detect peripheral blood-based, tumor-specific biomarkers, such as circulating tumor cells (CTCs) and circulating cell free tumor DNA (ctDNA). Despite the considerable advances and their multip...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Xiang, Qiu, Zhiqiang, Ji, Xiangwen, Ning, Weihai, An, Yihua, Wang, Shengdian, Zhang, Hongwei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7723582/
https://www.ncbi.nlm.nih.gov/pubmed/33313175
http://dx.doi.org/10.21037/atm-20-2047
_version_ 1783620370236964864
author Wang, Xiang
Qiu, Zhiqiang
Ji, Xiangwen
Ning, Weihai
An, Yihua
Wang, Shengdian
Zhang, Hongwei
author_facet Wang, Xiang
Qiu, Zhiqiang
Ji, Xiangwen
Ning, Weihai
An, Yihua
Wang, Shengdian
Zhang, Hongwei
author_sort Wang, Xiang
collection PubMed
description BACKGROUND: Over the last few years, great progress has been made in the development of key technologies to detect peripheral blood-based, tumor-specific biomarkers, such as circulating tumor cells (CTCs) and circulating cell free tumor DNA (ctDNA). Despite the considerable advances and their multiple clinical values, liquid biopsies are challenged by the very low concentrations of CTCs and ctDNA in blood samples. Additionally, blood biomarkers which were found using data-driven methods may only be effective in few datasets. METHODS: We firstly collected the genes which have expression correlations between blood and the other tissues/organs using Genotype-Tissue Expression (GTEx). Survival hazard genes and differential expression genes of each cancer type in The Cancer Genome Atlas (TCGA) were then selected by Cox regression model and Wilcoxon rank sum test, respectively. By combining the P values of two steps, several blood biomarkers can be inferred for each cancer type. After applying these potential blood biomarker sets to 13 datasets of blood samples from solid tumor patients using single sample gene set enrichment analyses (ssGSEA), we got an enrichment score (ES) for each sample. RESULTS: The inferred blood biomarker (BB infer) genes showed reliable predictive value in various malignancies. In all the blood samples that were analyzed, the ESs of positive BB Infer genes in cancer patients are higher than healthy people. Conversely, the ESs of negative BB Infer genes in cancer patients are lower than healthy people. Furthermore, lower ES of negative BB infer genes signify the dismal outcome of patients. CONCLUSIONS: We developed a novel solid tumor blood biomarker inference workflow for cancer screening and diagnosis. Moreover, we demonstrated the utility of this inference method in a series of blood sample datasets of solid tumor patients. These results suggested the potential value of this method in the screening, diagnosis and prognosis of cancers.
format Online
Article
Text
id pubmed-7723582
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-77235822020-12-10 A novel workflow for cancer blood biomarker identification Wang, Xiang Qiu, Zhiqiang Ji, Xiangwen Ning, Weihai An, Yihua Wang, Shengdian Zhang, Hongwei Ann Transl Med Original Article BACKGROUND: Over the last few years, great progress has been made in the development of key technologies to detect peripheral blood-based, tumor-specific biomarkers, such as circulating tumor cells (CTCs) and circulating cell free tumor DNA (ctDNA). Despite the considerable advances and their multiple clinical values, liquid biopsies are challenged by the very low concentrations of CTCs and ctDNA in blood samples. Additionally, blood biomarkers which were found using data-driven methods may only be effective in few datasets. METHODS: We firstly collected the genes which have expression correlations between blood and the other tissues/organs using Genotype-Tissue Expression (GTEx). Survival hazard genes and differential expression genes of each cancer type in The Cancer Genome Atlas (TCGA) were then selected by Cox regression model and Wilcoxon rank sum test, respectively. By combining the P values of two steps, several blood biomarkers can be inferred for each cancer type. After applying these potential blood biomarker sets to 13 datasets of blood samples from solid tumor patients using single sample gene set enrichment analyses (ssGSEA), we got an enrichment score (ES) for each sample. RESULTS: The inferred blood biomarker (BB infer) genes showed reliable predictive value in various malignancies. In all the blood samples that were analyzed, the ESs of positive BB Infer genes in cancer patients are higher than healthy people. Conversely, the ESs of negative BB Infer genes in cancer patients are lower than healthy people. Furthermore, lower ES of negative BB infer genes signify the dismal outcome of patients. CONCLUSIONS: We developed a novel solid tumor blood biomarker inference workflow for cancer screening and diagnosis. Moreover, we demonstrated the utility of this inference method in a series of blood sample datasets of solid tumor patients. These results suggested the potential value of this method in the screening, diagnosis and prognosis of cancers. AME Publishing Company 2020-11 /pmc/articles/PMC7723582/ /pubmed/33313175 http://dx.doi.org/10.21037/atm-20-2047 Text en 2020 Annals of Translational Medicine. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) .
spellingShingle Original Article
Wang, Xiang
Qiu, Zhiqiang
Ji, Xiangwen
Ning, Weihai
An, Yihua
Wang, Shengdian
Zhang, Hongwei
A novel workflow for cancer blood biomarker identification
title A novel workflow for cancer blood biomarker identification
title_full A novel workflow for cancer blood biomarker identification
title_fullStr A novel workflow for cancer blood biomarker identification
title_full_unstemmed A novel workflow for cancer blood biomarker identification
title_short A novel workflow for cancer blood biomarker identification
title_sort novel workflow for cancer blood biomarker identification
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7723582/
https://www.ncbi.nlm.nih.gov/pubmed/33313175
http://dx.doi.org/10.21037/atm-20-2047
work_keys_str_mv AT wangxiang anovelworkflowforcancerbloodbiomarkeridentification
AT qiuzhiqiang anovelworkflowforcancerbloodbiomarkeridentification
AT jixiangwen anovelworkflowforcancerbloodbiomarkeridentification
AT ningweihai anovelworkflowforcancerbloodbiomarkeridentification
AT anyihua anovelworkflowforcancerbloodbiomarkeridentification
AT wangshengdian anovelworkflowforcancerbloodbiomarkeridentification
AT zhanghongwei anovelworkflowforcancerbloodbiomarkeridentification
AT wangxiang novelworkflowforcancerbloodbiomarkeridentification
AT qiuzhiqiang novelworkflowforcancerbloodbiomarkeridentification
AT jixiangwen novelworkflowforcancerbloodbiomarkeridentification
AT ningweihai novelworkflowforcancerbloodbiomarkeridentification
AT anyihua novelworkflowforcancerbloodbiomarkeridentification
AT wangshengdian novelworkflowforcancerbloodbiomarkeridentification
AT zhanghongwei novelworkflowforcancerbloodbiomarkeridentification